Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Generic interferon-beta
Biogen Idec's long-acting beta interferon moves ahead in MS
Macrophage-specific chemokines induced via innate immunity by amino acid copolymers and their role in EAE.
2-chlorodeoxyadenosine (cladribine) induces apoptosis in human monocyte-derived dendritic cells.
Cutaneous adverse events in multiple sclerosis patients treated with daclizumab.
HLA-DRα1 Constructs Block CD74 Expression and MIF Effects in Experimental Autoimmune Encephalomyelitis.
Genmab announces positive top-line Phase II results of ofatumumab in multiple sclerosis
Intellectual enrichment lessens the effect of brain atrophy on learning and memory in multiple sclerosis.
Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cells.
Bench to bedside: tempering antigen-presenting cells in multiple sclerosis.
The prediction of human response to ONO-4641, a sphingosine 1-phosphate receptor modulator, from preclinical data based on pharmacokinetic-pharmacodynamic modeling.
Roche's MabThera approved for two vasculitis indications in UK
Soluble thrombomodulin levels in plasma of multiple sclerosis patients and their implication.
Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.
Receptos Completes Enrollment of RADIANCE Phase 3 Trial of Ozanimod in Relapsing Multiple Sclerosis
Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder Patients in Turkish Cohort: Demographic, Clinical, and Laboratory Features.
Biogen Reports Another Tecfidera PML Case
Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon Beta 1a dosages for multiple sclerosis.
lambda-Interferons and the single nucleotide polymorphisms: A milestone to tailor-made therapy for chronic hepatitis C.
Testing for urinary tract colonisation before high-dose corticosteroid treatment in acute multiple sclerosis relapses: prospective algorithm validation.
Decreased microglial activation in MS patients treated with glatiramer acetate.
Tumefactive Multiple Sclerosis presenting as Acute Ischemic Stroke.
Discontinuation of Disease-Modifying Treatment for Multiple Sclerosis
Altered Expression of Oligodendrocyte and Neuronal Marker Genes Predicts the Clinical Onset of Autoimmune Encephalomyelitis and Indicates the Effectiveness of Multiple Sclerosis-Directed Therapeutics.
Cognitive impairment in multiple sclerosis.

Pages